A report detailing clinic-level cost and quality of cancer care in Washington State is a first—adding its own stamp on efforts to measure value in oncology.
The FDA’s work to redefine ‘truthful and non-misleading’ communication may preempt state efforts.
Clinical benefits associated with new cancer therapies do not justify the high prices for the medications, and some value-based payment system is needed, according to a study published in the Journal of Oncology Practice. That’s especially true regarding incremental costs, the difference in total drug price between the novel medications and standard treatment.
Aimovig and other drugs targeting the CGRP neuropeptide aim to prevent migraines in a whole new way. But Aimovig’s cost may mean an obstacle course of prior authorization and step therapy.
A state lawmaker calls insulin prices ‘outrageous.’ PhRMA and BIO are fighting the law in court on grounds that it interferes with their patent rights.
At first patients didn’t care that much. Then the monitors improved, and studies showed improved outcomes. But CMS wouldn’t cover them unless they had a ‘nonadjunctive’ indication. Now some envision a time when fingersticks will be a thing of the past for many people with diabetes.